A recent survey has revealed that precision medicine programs are gaining ground as a critical investment within oncology health care systems.
A precision medicine support tool helps oncologists make clinical decisions and enroll patients in genotype-matched trials based on actionable mutations.
Almost one-third of surgeons admit that they rarely referred patients with early-stage breast cancer for genetic counseling prior to mastectomy.
A study testing the value of DNA sequencing as part of routine medical care showed that roughly one in five people carried a mutation linked with rare disease, but few actually benefited from that information.
The FDA and CancerLinQ—a big data repository and clinical decision support platform in oncology—have entered a partnership for studying real-world impacts of precision medicine therapies for cancer care.
Thousands of patients who could have received personalized medicine for their cancer tumors were instead given chemotherapy drugs with more toxic side effects and less therapeutic benefit.
While most oncologists say genomic sequencing is an important advance, close to two thirds say only a small percentage of their patients might benefit.
High-throughput genomic analyses may improve outcomes in patients with types of metastatic cancer, according to results of a recent trial published in Cancer Discovery.